Mostaan Saied, Ghasemzadeh Abbas, Sardari Soroush, Shokrgozar Mohammad Ali, Nikbakht Brujeni Gholamreza, Abolhassani Mohsen, Ehsani Parastoo, Asadi Karam Mohammad Reza
Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Avicenna J Med Biotechnol. 2020 Jul-Sep;12(3):140-147.
() is the highly contagious causative agent of a broad range of diseases in animals as well as an occasional human pathogen. Economically significant infections caused by include avian fowl cholera, rabbit snuffles, and hemorrhagic septicemia in cattle, goats and pigs. Chemotherapy of pasteurellosis infections has some limitations, such as high cost of treatment, low efficacy, and the possibility of therapy failure due to antibiotic resistance. Prophylactic immunization offers a safe and effective preventive measure in case of zoonotic diseases. Bacterins, live attenuated and some old traditional vaccines against pasteurellosis remain in use today, beside their limitations. However, the past few years have seen significant progress in research to identify modern, effective vaccine candidates, but there is no new vaccine produced by new strategies. While scientists should struggle with a lot of aspects to design vaccine producing strategies, this review shows how pasteurellosis vaccine evolved and the limitations in its application which need to be overcome.
()是多种动物疾病的高传染性病原体,偶尔也会感染人类。由其引起的具有经济重要性的感染包括禽霍乱、兔鼻炎以及牛、山羊和猪的出血性败血症。巴氏杆菌病感染的化疗存在一些局限性,如治疗成本高、疗效低以及因抗生素耐药性导致治疗失败的可能性。预防性免疫是预防人畜共患病的一种安全有效的措施。尽管存在局限性,但针对巴氏杆菌病的菌苗、减毒活疫苗和一些传统老疫苗至今仍在使用。然而,在过去几年中,在寻找现代有效候选疫苗的研究方面取得了重大进展,但尚无通过新策略生产的新疫苗。虽然科学家在设计疫苗生产策略时需要应对许多方面的问题,但本综述展示了巴氏杆菌病疫苗的演变过程及其应用中需要克服的局限性。